32.16
0.05 (0.16%)
| Penutupan Terdahulu | 32.11 |
| Buka | 32.30 |
| Jumlah Dagangan | 287,680 |
| Purata Dagangan (3B) | 693,285 |
| Modal Pasaran | 1,846,765,440 |
| Harga / Pendapatan (P/E TTM) | 12.27 |
| Harga / Pendapatan (P/E Ke hadapan) | 9.41 |
| Harga / Jualan (P/S) | 2.72 |
| Harga / Buku (P/B) | 2.78 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Aug 2025 |
| Margin Keuntungan | 20.50% |
| Margin Operasi (TTM) | 30.45% |
| EPS Cair (TTM) | 2.62 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 19.50% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 18.90% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 24.63% |
| Nisbah Semasa (MRQ) | 3.67 |
| Aliran Tunai Operasi (OCF TTM) | 222.67 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 143.41 M |
| Pulangan Atas Aset (ROA TTM) | 12.81% |
| Pulangan Atas Ekuiti (ROE TTM) | 24.71% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menurun |
| Biotechnology (Global) | Bercampur | Menurun | |
| Stok | Harmony Biosciences Holdings, I | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -1.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | 1.50 |
|
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 11.10% |
| % Dimiliki oleh Institusi | 92.80% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 61.00 (Oppenheimer, 89.68%) | Beli |
| Median | 49.00 (52.36%) | |
| Rendah | 48.00 (Mizuho, 49.25%) | Beli |
| 48.00 (UBS, 49.25%) | Beli | |
| Purata | 52.20 (62.31%) | |
| Jumlah | 5 Beli | |
| Harga Purata @ Panggilan | 33.38 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Deutsche Bank | 10 Jul 2025 | 55.00 (71.02%) | Beli | 34.33 |
| Oppenheimer | 02 Jun 2025 | 61.00 (89.68%) | Beli | 35.56 |
| Mizuho | 15 May 2025 | 48.00 (49.25%) | Beli | 34.23 |
| Needham | 07 May 2025 | 49.00 (52.36%) | Beli | 33.44 |
| 06 May 2025 | 49.00 (52.36%) | Beli | 32.05 | |
| UBS | 28 Apr 2025 | 48.00 (49.25%) | Beli | 29.36 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |